SA
KPTIQ

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Karyopharm Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel therapies for cancer and other serious diseases. Its lead product, Xpovio (selinexor), is a first-in-class oral selective inhibitor of nuclear export, which has shown efficacy in treating multiple myeloma and diffuse large B-cell lymphoma. The company operates primarily in the United States and has a growing pipeline of drug candidates targeting various hematological malignancies.

HealthcareMedical - Pharmaceuticalslow - The company has high fixed costs associated with R&D and regulatory compliance, which can lead to significant operating leverage but also increases risk if sales do not meet projections.

Business Overview

01Xpovio sales - 100%

Karyopharm generates revenue primarily through the sale of its lead drug Xpovio, which is priced at approximately $20,000 per year per patient. The company has established partnerships for distribution and is focused on expanding its market presence through clinical trials and regulatory approvals for additional indications.

What Moves the Stock

Regulatory approvals for new indications of Xpovio

Clinical trial results for pipeline candidates

Partnership announcements for distribution or co-development

Market adoption rates of Xpovio in oncology

Watch on Earnings
Number of patients treated with XpovioQuarterly revenue from XpovioProgress in clinical trials for pipeline drugs

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption in cancer treatment methodologies

Emergence of new therapies from competitors targeting the same indications

Pricing pressure from generic alternatives

Liquidity risk due to ongoing R&D expenditures without consistent revenue

Potential for increased debt if additional financing is required for trials

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The demand for cancer therapies is relatively inelastic; however, broader economic conditions can impact healthcare spending.

Interest Rates

Moderate - Rising interest rates can increase the cost of capital for R&D funding and may impact stock valuations, but the direct impact on demand for cancer therapies is limited.

Credit

minimal - The company is not heavily reliant on credit markets for operations, though access to financing is important for ongoing clinical trials.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in the biotech space.

high - The stock has shown significant volatility, particularly in response to clinical trial results and regulatory news.

Key Metrics to Watch
Xpovio patient enrollment rates
Clinical trial success rates
Revenue growth from Xpovio
Partnership developments
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.